AccessMyLibraryBrowseBBusiness Wire Taro Receives FDA Approval for Clotrimazole and Betamethasone Dipropionate Lotion ANDA; Generic Equivalent to Lotrisone Lotion.
Taro Receives FDA Approval for Clotrimazole and Betamethasone Dipropionate Lotion ANDA; Generic Equivalent to Lotrisone Lotion.
Publication: Business Wire
Publication Date: 29-JUL-04
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for clotrimazole and betamethasone dipropionate lotion ("C/B lotion").
Taro's C/B lotion is bioequivalent to Schering's Lotrisone(R) lotion. C/B lotion...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
